Korea’s Government-Funded Venture into Oncology
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Established in 1960, CHA Health Systems (CHS) opened its first women’s medical center in Seoul, South Korea. CHS has received worldwide recognition and accolades for its excellence in clinical research and accomplishments in the fields of obstetrics and gynecology. It owns and operates, among others: Hollywood Presbyterian Medical Center, one of the largest privately-owned hospital in Los Angeles and 8 general acute-care hospital facilities throughout Korea. CHS continued its international expansion and formed CHAUM, a premier anti-aging center and 5 fertility treatment and research centers in the U.S. and Korea. The Company’s activities also include various medical and biotech ventures, including a healthcare investment firm, CHA Bio & Diostech, one of the largest biotechs listed in KOSDAQ.
CHS also introduces a premier anti-aging center, CHAUM, offering various treatments including western medicine, alternative medicine, stem-cell therapies, exercise prescription, and food therapies, targeting issues related to optimum health and wellness. It also operates a global CHAUM clinical trial center, the world’s only one-stop clinical trial center for regenerative medicine. In this center, GMP facility, surgery room, recovery room, treatment room, and in-hospitalization facility are centrally located for convenience and quality care. Its customized clinical trial services and state-of-the art facilities for the development of regenerative medicine are a major supplier to many biotech companies worldwide, which offers opportunities for small and large companies to carry out proof of concept studies and early phase clinical trials at substantial savings in time and money.
With the ultimate vision of becoming a global leader in the next generation of healthcare services, CHS continues to stay at the forefront of medical services by building its global network of hospitals/clinics and research institutes for the advancement of bio-medicine and bio-ventures.
Contact Details
Dong-kun Lee, Corporate Planning
335 Pangyo-Ro, Bundang-Gu, Seongnam City, Kyunggi-Do, Republic of Korea
Tel. (+82)31-881-7370 Cell (+82)10-9261-6160 Fax. (+82)31-881-7379
E-mail. ddkk.lee@chamc.co.kr
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech…
Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine.…
Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future…
Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This…
Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of…
Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the…
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Jongmoon Kim, CEO of ToolGen discusses the potential for their CRISPR technology to revolutionize not only therapy for genetic illnesses, but also agriculture. Kim explains his move from information technology…
JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of…
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
See our Cookie Privacy Policy Here
